NUTX Valuation

Nutex Health Inc

Add to Watchlist

Advanced Chart

90.050

+0.54(0.603%)1D

Overview
Forecast
Valuation
Earnings

NUTX Relative Valuation

NUTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NUTX is overvalued; if below, it's undervalued.

Historical Valuation

Nutex Health Inc (NUTX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.64 is considered Undervalued compared with the five-year average of -27.45. The fair price of Nutex Health Inc (NUTX) is between 101.36 to 168.69 according to relative valuation methord. Compared to the current price of 90.05 USD , Nutex Health Inc is Undervalued By 11.16%.

Relative Value

Fair Zone

101.36-168.69

Current Price：90.05

11.16%

Undervalued

8.26

Trailing

Forward

3.35

EV/EBITDA

Nutex Health Inc. (NUTX) has a current EV/EBITDA of 3.35. The 5-year average EV/EBITDA is 66.16. The thresholds are as follows: Strongly Undervalued below -159.28, Undervalued between -159.28 and -46.56, Fairly Valued between 178.89 and -46.56, Overvalued between 178.89 and 291.61, and Strongly Overvalued above 291.61. The current Forward EV/EBITDA of 3.35 falls within the Historic Trend Line -Fairly Valued range.

3.09

EV/EBIT

Nutex Health Inc. (NUTX) has a current EV/EBIT of 3.09. The 5-year average EV/EBIT is 120.50. The thresholds are as follows: Strongly Undervalued below -1150.21, Undervalued between -1150.21 and -514.85, Fairly Valued between 755.86 and -514.85, Overvalued between 755.86 and 1391.21, and Strongly Overvalued above 1391.21. The current Forward EV/EBIT of 3.09 falls within the Historic Trend Line -Fairly Valued range.

0.64

Nutex Health Inc. (NUTX) has a current PS of 0.64. The 5-year average PS is 3.31. The thresholds are as follows: Strongly Undervalued below -11.73, Undervalued between -11.73 and -4.21, Fairly Valued between 10.82 and -4.21, Overvalued between 10.82 and 18.34, and Strongly Overvalued above 18.34. The current Forward PS of 0.64 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Nutex Health Inc. (NUTX) has a current P/OCF of 0.00. The 5-year average P/OCF is 1.65. The thresholds are as follows: Strongly Undervalued below -5.17, Undervalued between -5.17 and -1.76, Fairly Valued between 5.06 and -1.76, Overvalued between 5.06 and 8.47, and Strongly Overvalued above 8.47. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Nutex Health Inc. (NUTX) has a current P/FCF of 0.00. The 5-year average P/FCF is -98.34. The thresholds are as follows: Strongly Undervalued below -699.42, Undervalued between -699.42 and -398.88, Fairly Valued between 202.20 and -398.88, Overvalued between 202.20 and 502.74, and Strongly Overvalued above 502.74. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Nutex Health Inc (NUTX) has a current Price-to-Book (P/B) ratio of 2.52. Compared to its 3-year average P/B ratio of 3.40 , the current P/B ratio is approximately -25.83% higher. Relative to its 5-year average P/B ratio of 6.10, the current P/B ratio is about -58.65% higher. Nutex Health Inc (NUTX) has a Forward Free Cash Flow (FCF) yield of approximately 13.96%. Compared to its 3-year average FCF yield of 5.12%, the current FCF yield is approximately 172.62% lower. Relative to its 5-year average FCF yield of 4.94% , the current FCF yield is about 182.53% lower.

2.52

P/B

Median3y

3.40

Median5y

6.10

13.96

FCF Yield

Median3y

5.12

Median5y

4.94

Competitors Valuation Multiple

The average P/S ratio for NUTX's competitors is 1.67, providing a benchmark for relative valuation. Nutex Health Inc Corp (NUTX) exhibits a P/S ratio of 0.64, which is -61.58% above the industry average. Given its robust revenue growth of 213.98%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Sonida Senior Living Inc

Performance Decomposition

Market capitalization of NUTX increased by 320.99% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 0.26 to 7.50.

The secondary factor is the Revenue Growth, contributed 213.98%to the performance.

Overall, the performance of NUTX in the past 1 year is driven by P/E Change. Which is more unsustainable.

213.98%

67.45M → 211.79M

Revenue Growth

-2710.00%

-0.80 → 20.88

Margin Expansion

2817.01%

0.26 → 7.50

P/E Change

320.99%